Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study

• Main Authors: Germán Áñez (Author), James Hedrick (Author), Michael W. Simon (Author), Shane Christensen (Author), Robert Jeanfreau (Author), Eddy Yau (Author), Judy Pan (Author), Emilia Jordanov (Author), Mandeep S. Dhingra (Author)
• Format: Book
• Published: Taylor & Francis Group, 2020-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) was assessed as a booster in this Phase III trial (NCT02752906). Quadrivalent meningococcal conjugate vaccine (MCV4)-primed individuals aged ≥15 y (n = 810) were randomized 1:1 to receive a single booster dose of MenACYW-TT...